Objectives: This study aimed to determine the genetic environment and characterize plasmid carrying a novel VIM-type β-lactamase (VIM-84) in a multidrug-resistant Pseudomonas monteilii (P. monteilii) isolate obtained from the human gut through whole-genome sequencing.
Methods: DNA extraction of P. monteilii L2757hy was performed using the Genomic DNA Isolation Kit (QIAGEN, Hilden, Germany). Whole-genome sequencing was performed by Illumina NovaSeq 6000 and Oxford Nanopore platforms. The transferability of resistance genes was screened as single clonal on Mueller Hinton Agar (MHA) plates containing rifampicin and meropenem. Verification was performed using matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI/TOF-MS) and polymerase chain reaction (PCR) with Pseudomonas aeruginosa PAO1Ri as the recipient strain.
Results: L2757hy was identified as P. monteilii through sequencing and average nucleotide identity (ANI) analysis. The genome was assigned as ST147 and comprised a 6, 130, 057 bp chromosome with a GC content of 61.8% and a 49, 704 bp plasmid. Several resistance genes, including bla, aac(6')-IIa and tmexCD-toprJ, as well as virulence genes, such as iroN and wzaJ, were identified on the chromosome. A novel VIM-type bla was found on the plasmid, which was previously identified in Pseudomonas aeruginosa. Plasmid harboring bla was untypable, and it could be transferred to P. aeruginosa PAO1Ri and was associated with a class I integron with the genetic environment intI1-bla-tniR-tniQ-tniB-tniA, likely derived from Tn402.
Conclusions: Our study revealed that the novel bla gene was harbored by P. monteilii rather than P. aeruginosa. We suggested that P. monteilii may serve as a reservoir for resistance genes. © 2024 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jgar.2024.09.007 | DOI Listing |
J Glob Antimicrob Resist
December 2024
Department of Pulmonary and Critical Care Medicine, Ningbo Medical Center Lihuili Hospital, Ningbo, China. Electronic address:
J Antimicrob Chemother
May 2024
Department of Molecular Microbiology, National Medicines Institute, Chełmska 30/34, Warsaw 00-725, Poland.
Objectives: To characterize VIM-type metallo-β-lactamase (MBL)-encoding genomic islands (GIs) in Pseudomonas aeruginosa and P. putida group isolates from Polish hospitals from 2001-2015/16.
Methods: Twelve P.
Microbiol Res
January 2024
The Hong Kong Polytechnic University Shenzhen Research Institute, Shenzhen, PR China; State Key Lab for Chemical Biology and Drug Discovery, and the Department of Food Science and Nutrition, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong. Electronic address:
Microbiol Spectr
September 2023
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
J Chemother
May 2023
Microbiology and Virology Unit, University Hospital Città della Salute e della Scienza di Torino, Turin, Italy.
This study was aimed at analyzing the prevalence of metallo-β-lactamase-producing Gram-negative bacilli (MBL-GNB) and evaluating both activity of cefiderocol and synergy of novel β-lactam-β-lactamase inhibitor-based combinations. Carbapenemase-producing Enterobacterales and meropenem-non-susceptible clinical strains were collected (2019-2020) and prevalence of MBL-producers investigated. Activity of cefiderocol was evaluated and synergistic effects of cefiderocol in combination with ceftazidime/avibactam aztreonam plus ceftazidime/avibactam meropenem/vaborbactam plus aztreonam were compared.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!